Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-23T09:57:21.294Z Has data issue: false hasContentIssue false
  • English
  • Français

Challenges in the Management of Infections due to Carbapenem-Resistant Enterobacteriaceae

Published online by Cambridge University Press:  10 May 2016

Dimitri M. Drekonja ,
Susan E. Beekmann ,
Sean Elliott ,
Deepa Mukundan ,
Hari Polenakovik ,
Marnie E. Rosenthal ,
Pranita D. Tamma ,
Philip M. Polgreen  and
Scott J. Weissman
Dimitri M. Drekonja*
Affiliation:
Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota Department of Medicine, University of Minnesota, Minneapolis, Minnesota
Susan E. Beekmann
Affiliation:
Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa
Sean Elliott
Affiliation:
Department of Pediatrics, University of Arizona, Tucson, Arizona
Deepa Mukundan
Affiliation:
Department of Pediatrics and Department of Medical Microbiology and Immunology, University of Toledo College of Medicine, Toledo, Ohio
Hari Polenakovik
Affiliation:
Department of Internal Medicine, Boonshoft School of Medicine, Wright State University, Dayton, Ohio
Marnie E. Rosenthal
Affiliation:
Department of Medicine, Section of Infectious Diseases, Jersey Shore University Medical Center, Neptune, New Jersey
Pranita D. Tamma
Affiliation:
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland
Philip M. Polgreen
Affiliation:
Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa
Scott J. Weissman
Affiliation:
Center for Childhood Infections and Prematurity Research, Seattle Children's Research Institute, Seattle, Washington
*
Infectious Diseases (111F), Veterans Affairs Medical Center, 1 Veterans Drive, Minneapolis, MN 55417 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) infections are increasing and are associated with considerable morbidity and mortality. Members of the Emerging Infections Network treating CRE encountered difficulties in obtaining laboratory results and struggled with limited treatment options. In addition, many treated patients experienced an alarming degree of drug toxicity from CRE therapies.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 35 , Issue 4: Special Topic Issue: Carbapenem-Resistant Enterobacteriaceae and Multidrug-Resistant Organisms , April 2014 , pp. 437 - 439
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013;62(9):165–170.Google Scholar
2. Boucher, HW, Talbot, GH, Bradley, JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1–12.Google Scholar
3. Emerging Infections Network (EIN). Carbapenem-Resistant Enterobacteriaceae Infections: A Case Series. Iowa City, IA: EIN, 2012. http://www.int-med.uiowa.edu/Research/EIN/CREcaseseries_form.pdf.Google Scholar
4. Lim, LM, Ly, N, Anderson, D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;30(12):1279–1291.Google Scholar
5. Gardiner, D, Dukart, G, Cooper, A, Babinchak, T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010;50(2):229–238.Google Scholar
6. Prasad, P, Sun, J, Danner, RL, Natanson, C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54(12):1699–1709.Google Scholar
7. Durante-Mangoni, E, Signoriello, G, Andini, R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57(3):349–358.Google Scholar
8. Bratu, S, Landman, D, Haag, R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165(12):1430–1435.Google Scholar